SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-041898
Filing Date
2021-08-06
Accepted
2021-08-06 07:10:41
Documents
14
Period of Report
2021-08-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kymr-8k_20210806.htm   iXBRL 8-K 41523
2 EX-99.1 kymr-ex991_15.htm EX-99.1 233741
3 GRAPHIC gxb5hzlyhfa3000001.jpg GRAPHIC 4793
  Complete submission text file 0001564590-21-041898.txt   433526

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA kymr-20210806.xsd EX-101.SCH 5776
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE kymr-20210806_lab.xml EX-101.LAB 20227
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kymr-20210806_pre.xml EX-101.PRE 12084
7 EXTRACTED XBRL INSTANCE DOCUMENT kymr-8k_20210806_htm.xml XML 3696
Mailing Address 300 TECHNOLOGY SQUARE 2ND FLOOR CAMBRIDGE MA 02139
Business Address 300 TECHNOLOGY SQUARE 2ND FLOOR CAMBRIDGE MA 02139 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

IRS No.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 211150533
SIC: 2836 Biological Products, (No Diagnostic Substances)